How to Screen Sexual Dysfunction in Major Depressive Disorder on Antidepressants
How should clinicians assess sexual dysfunction in adults with major depressive disorder who report inadequate antidepressant therapy response?
Sexual dysfunction is common in major depressive disorder and is often underreported, especially during antidepressant treatment. In this study population with inadequate antidepressant therapy response, 82.5% met criteria for sexual dysfunction at baseline, supporting structured assessment rather than relying on spontaneous patient report.
-
Identify patients with inadequate antidepressant response
Apply this workflow to adults with major depressive disorder who remain symptomatic despite antidepressant therapy. In the study, inadequate response meant less than 50% improvement after at least 6 weeks of antidepressant monotherapy, with failure of 1 or 2 antidepressant courses in the current depressive episode.
-
Measure sexual function with the CSFQ-14
Use the 14-item Changes in Sexual Functioning Questionnaire to assess sexual functioning rather than relying only on spontaneous adverse-effect reporting. The study used CSFQ-14 Total score as the main sexual-function outcome, with higher scores indicating better sexual functioning.
-
Classify baseline sexual dysfunction by sex-specific cutoff
Interpret the CSFQ-14 Total score using the study thresholds for sexual dysfunction. Scores of 41 or lower in female patients and 47 or lower in male patients were categorized as sexual dysfunction.
-
Review affected sexual-function domains
Look beyond the total score and examine the CSFQ-14 domains assessed in the study: pleasure, desire/frequency, desire/interest, arousal/excitement, and orgasm/completion. This helps define whether the patient’s difficulties are broad or concentrated in desire, arousal, or orgasmic function.
-
Reassess after treatment change over 6 weeks
If treatment is modified, repeat the CSFQ-14 over the short term to track whether sexual functioning improves, remains stable, or worsens. In the article, sexual function was reassessed at Day 43, and a 2- or 3-point difference in CSFQ-14 Total score versus placebo was described as clinically meaningful.
-
Interpret sexual-function change alongside depressive symptoms
Evaluate sexual-function findings together with change in depression severity rather than assuming a fully independent sexual effect. In the study, change in CSFQ-14 Total score had a moderate association with change in MADRS Total score at Day 22 and Day 43, and most of the observed treatment effect on sexual function appeared mediated through mood improvement.
Clinical Considerations
- The sexual-function analyses were post hoc and exploratory, with no adjustment for multiplicity, so P values were nominal and descriptive.
- Sexual dysfunction was measured by self-report, which may be influenced by reporting bias, recall inaccuracy, or reluctance to disclose sensitive symptoms.
- Sexual activity and partnership were not assessed, which limits interpretation of sexual-function scores in individual patients.
- The study population was predominantly White and included relatively few men, so subgroup findings, especially in men, may not generalize broadly.
Bottom Line
In adults with major depressive disorder and inadequate antidepressant response, sexual dysfunction should be screened directly with the CSFQ-14 using sex-specific cutoffs because it is common and easy to miss if clinicians wait for spontaneous reporting.
